NYSE:LLY

More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

Retrieved on: 
Sunday, March 10, 2024
Diagnosis, Pigment, LLY, Weill Cornell Medicine, Atopic dermatitis, Health equity, Alaska Natives, Patient, Education, PDCA, Advocate, Diversity, Adherence, Immunology, Research, American Academy, Human, Weill Cornell Medical Center, Dermatitis, African, Skin, Safety, Lilly, Eli Lilly and Company, AAD, Health, IGA, Almirall, Pharmaceutical industry

In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.

Key Points: 
  • In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
  • These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
  • "People with skin of color are disproportionately affected by atopic dermatitis, often experiencing more severe symptoms, a delay in diagnosis and a lengthier timeframe to find appropriate treatment.
  • "With these initial results, Lilly is taking a step toward investigating the needs of people with skin of color affected by atopic dermatitis."

Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care

Retrieved on: 
Thursday, March 7, 2024
Big Night, Eli Lilly and Company, Alzheimer's disease, Obesity, FDA, Health, Lilly, Get Better, Patient, Medicine, Disease, Science, Patient safety, Research, LLY, Shame, Pharmaceutical industry

INDIANAPOLIS, March 7, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity. Earlier this year, Lilly launched Get Better to reinforce its commitment to discovering and making medicines that give people a chance at better health.

Key Points: 
  • INDIANAPOLIS, March 7, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity.
  • Earlier this year, Lilly launched Get Better to reinforce its commitment to discovering and making medicines that give people a chance at better health.
  • As a continuation of the larger campaign, Lilly will air two films - Shame and Big Night .
  • Shame, unveiled during Obesity Care Week, is designed to increase the dialogue about obesity as a serious disease and reinforce that there is no place for shame in the conversation around it.

Thinking about buying stock in SoundHound AI, Eli Lilly, Dell Technologies, NKGen Biotech, or Riot Platforms?

Retrieved on: 
Wednesday, March 6, 2024
Multimedia

Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.

Key Points: 
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
  • We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

Lilly to Participate in Cowen's 44th Annual Health Care Conference

Retrieved on: 
Tuesday, February 20, 2024
Eli Lilly and Company, LLY, Conference

INDIANAPOLIS, Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024.

Key Points: 
  • INDIANAPOLIS, Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024.
  • Anat Ashkenazi, executive vice president and chief financial officer, will take part in a fireside chat at 9:10 a.m., Eastern time.
  • A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay of the presentation will be available on this same website for approximately 90 days.

Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

Retrieved on: 
Thursday, February 15, 2024

A recent report from Allied Market Research projected that the Global Fibromyalgia Treatment Market size, which was valued at $3.1 billion in 2022, is estimated to reach $4.6 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.0% from 2023 to 2032.

Key Points: 
  • A recent report from Allied Market Research projected that the Global Fibromyalgia Treatment Market size, which was valued at $3.1 billion in 2022, is estimated to reach $4.6 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.0% from 2023 to 2032.
  • The report said: “The rising incidence and recognition of fibromyalgia as a chronic pain condition have driven the demand for effective treatment options.
  • Fibromyalgia is more commonly diagnosed in older adults, and as the global population ages, there is a growing prevalence of this condition.
  • Allied Market Research continued: “As more individuals are identified with fibromyalgia, there is a greater demand for appropriate treatment options.

Philip Johnson to Retire as Lilly Treasurer

Retrieved on: 
Friday, February 9, 2024
LLY, Institutional Investor, Mentorship, Eli Lilly and Company, Lilly, Patient, Pharmaceutical industry

INDIANAPOLIS, Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity.

Key Points: 
  • INDIANAPOLIS, Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity.
  • "Phil has had a meaningful impact on Lilly over the last 28 years," said Anat Ashkenazi, executive vice president and chief financial officer at Lilly.
  • Throughout his tenure, Johnson supported a variety of operations, including Lilly affiliates in Japan and Spain, global manufacturing and quality organizations, and business development activities.
  • He led Lilly's investor relations group for 11 years and was consistently named Top Investor Relations Officer by Institutional Investor.

Thinking about buying stock in Foghorn Therapeutics, Oscar Health, Eli Lilly And Co, Palo Alto Networks, or CN ENERGY GROUP?

Retrieved on: 
Thursday, February 8, 2024
Multimedia

Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.

Key Points: 
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
  • We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Retrieved on: 
Thursday, January 25, 2024
Patient, Research, Executive Committee, Woman, Eli Lilly and Company, Quality control, Retirement, LLY, Pharmaceutical industry

INDIANAPOLIS, Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024.

Key Points: 
  • INDIANAPOLIS, Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024.
  • "Johna's career has been built on her commitment to ensuring that our medicines are produced with the highest quality standards.
  • "During her tenure as leader of Global Quality, Johna has overseen significant expansion, modernization of systems and improvements in our processes and team.
  • Norton has been with Lilly since 1990, starting as an analytical chemist and moving on to hold various leadership positions in quality assurance and quality control.

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

Retrieved on: 
Tuesday, January 23, 2024
Child, Hearing loss, Lilly, Clinical trial, Gene, Medicine, Sant Joan, ABR, Eli Lilly and Company, Genetic testing, Division, HL, Hospital, ARO, FDA, Physician, Late, Hearing, Research, Diagnosis, LLY, SVP, Pharmaceutical industry

INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, an individual with a decade-plus history of profound hearing loss. Results, including initial data from a second participant to receive AK-OTOF, will be presented during the Late Breaking Presidential Symposium at the 2024 Association for Research in Otolaryngology (ARO) MidWinter Meeting.

Key Points: 
  • Results, including initial data from a second participant to receive AK-OTOF, will be presented during the Late Breaking Presidential Symposium at the 2024 Association for Research in Otolaryngology (ARO) MidWinter Meeting.
  • Both the surgical administration procedure and the investigational therapy were well tolerated, and no serious adverse events were reported.
  • Millions of individuals worldwide have disabling hearing loss because one of their genes generates an incorrect or incomplete version of a protein the ear requires for hearing.
  • OTOF-mediated hearing loss is the first monogenic form of hearing loss to be investigated as part of a gene therapy clinical trial.

Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance

Retrieved on: 
Tuesday, January 23, 2024
Eli Lilly and Company, LLY, Lilly, Pharmaceutical industry

INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024.

Key Points: 
  • INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024.
  • Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance.
  • Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay will also be available on the website following the conference call.